secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001818331-24-000041
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GeneDx Q2 revenue $68.9M (+52% YoY); raises FY24 revenue guidance to $255-265M
------------------------------------------------------------------------------

- Exome/genome test revenue $50.7M (+77% YoY), volume 18,017 (+52% YoY).
- Adjusted gross margin from continuing ops 62% (up from 37% YoY).
- Adjusted net loss narrowed to $2.7M, an improvement of 93% YoY.
- GAAP net loss $29.2M including $13M one-time litigation charge.
- Raises FY2024 revenue guidance to $255-265M; reiterates path to profitability in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833124000041/0001818331-24-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833124000041/wgs-20240730.htm
  HTML page:      https://secwatch.observer/filing/0001818331-24-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer